Flexion Therapeutics, Inc. (FLXN) Stock Rating Reaffirmed by Needham & Company LLC
Flexion Therapeutics, Inc. (NASDAQ:FLXN)‘s stock had its “buy” rating restated by stock analysts at Needham & Company LLC in a research note issued on Sunday. They presently have a $36.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 49.25% from the stock’s current price.
FLXN has been the subject of a number of other reports. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Royal Bank Of Canada reissued an “outperform” rating and issued a $44.00 price target on shares of Flexion Therapeutics in a report on Thursday, August 10th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and set a $35.00 target price (up from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $31.50.
Shares of Flexion Therapeutics (NASDAQ:FLXN) opened at 24.12 on Friday. Flexion Therapeutics has a 1-year low of $15.93 and a 1-year high of $29.41. The company’s market cap is $769.55 million. The firm’s 50-day moving average is $23.25 and its 200-day moving average is $22.01.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). On average, equities analysts forecast that Flexion Therapeutics will post ($3.70) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Flexion Therapeutics, Inc. (FLXN) Stock Rating Reaffirmed by Needham & Company LLC” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/17/flexion-therapeutics-inc-flxn-stock-rating-reaffirmed-by-needham-company-llc.html.
In other Flexion Therapeutics news, insider Yamo Deniz bought 3,000 shares of Flexion Therapeutics stock in a transaction dated Friday, September 1st. The stock was acquired at an average cost of $24.15 per share, with a total value of $72,450.00. Following the purchase, the insider now directly owns 5,000 shares in the company, valued at approximately $120,750. The acquisition was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders have bought 5,375 shares of company stock valued at $131,575. Corporate insiders own 15.98% of the company’s stock.
Several hedge funds have recently made changes to their positions in FLXN. Fiduciary Trust Co. acquired a new position in shares of Flexion Therapeutics during the 2nd quarter worth approximately $101,000. IFP Advisors Inc raised its stake in Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,000 shares during the last quarter. Advisor Group Inc. raised its stake in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares during the last quarter. Voya Investment Management LLC raised its stake in Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after purchasing an additional 2,651 shares during the last quarter. Finally, BB&T Securities LLC acquired a new position in Flexion Therapeutics in the 2nd quarter valued at $289,000. 82.75% of the stock is owned by institutional investors and hedge funds.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.